Article

STAAR toric IOL receives CE mark

STAAR Surgical Co. has received CE mark approval for a single-piece toric IOL (nanoFLEX Toric Collamer Single Piece IOL). The IOL, which is designed for patients who have cataracts and astigmatism, was approved for correction of 1.0 D to 4.0 D of cylinder in 0.5-D steps.

Monrovia, CA-STAAR Surgical Co. has received CE mark approval for a single-piece toric IOL (nanoFLEX Toric Collamer Single Piece IOL). The implant, which is designed for patients who have cataracts and astigmatism, was approved for correction of 1.0 to 4.0 D of cylinder in 0.5-D steps.

First shipments of the IOL are scheduled for the first quarter of next year.

“Approval of [the device] in Europe is the first step in a process to establish the [single-piece toric IOL] globally as an improved option for cataract patients who also have astigmatism,” said Barry G. Caldwell, STARR Surgical president and chief executive officer. “We have also been in discussions with the FDA about the requirements to obtain approval of the [single-piece toric IOL] in the United States.”

According to STARR Surgical, approval of the cylinder range from 1.0 to 4.0 D allows the lens to correct vision in more than 95% of eyes with clinically significant astigmatism.

Collamer is a trademark for STAAR’s proprietary biocompatible collagen copolymer lens material.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
© 2025 MJH Life Sciences

All rights reserved.